Research

Gene discovery unlocks mysteries of our immunity

Australia's national science agency CSIRO has identified a new gene that plays a critical role in regulating the body's immune response to infection and disease.

Photo
The C6orf106 or 'C6' gene.
Source: CSIRO

The discovery could lead to the development of new treatments for influenza, arthritis and even cancer. The gene, called C6orf106 or "C6", controls the production of proteins involved in infectious diseases, cancer and diabetes. The gene has existed for 500 million years, but its potential is only now understood. "Our immune system produces proteins called cytokines that help fortify the immune system and work to prevent viruses and other pathogens from replicating and causing disease," CSIRO researcher Dr. Cameron Stewart said. "C6 regulates this process by switching off the production of certain cytokines to stop our immune response from spiralling out of control. The cytokines regulated by C6 are implicated in a variety of diseases including cancer, diabetes and inflammatory disorders such as rheumatoid arthritis."

The discovery helps improve our understanding of our immune system, and it is hoped that this understanding will enable scientists to develop new, more targeted therapies.

"There are still thousands of genes that we know very little about."

Dr. Rebecca Ambrose

Dr. Rebecca Ambrose was part of the CSIRO team that discovered the gene, and co-authored the recent paper announcing the discovery in the Journal of Biological Chemistry. "Even though the human genome was first fully sequenced in 2003, there are still thousands of genes that we know very little about," said Ambrose, who is now based at the Hudson Institute of Medical Research. "It's exciting to consider that C6 has existed for more than 500 million years, preserved and passed down from simple organisms all the way to humans. But only now are we gaining insights into its importance."

Having discovered the function of C6, the researchers are awarded the privilege of naming it, and are enlisting the help of the community to do so. "The current name, C6orf106, reflects the gene's location within the human genome, rather than relating to any particular function," Dr. Stewart said. "We think we can do better than that, and are inviting suggestions from the public."

The breakthrough builds on decades of work in infectious diseases, by researchers from CSIRO, Australia's national science agency.

Source:  CSIRO

02.07.2018

Read all latest stories

Related articles

Photo

COVID-19 infections

Genetic network analysis provides 'snapshot' of pandemic origins

Researchers from Cambridge, UK, and Germany have reconstructed the early “evolutionary paths” of COVID-19 in humans – as infection spread from Wuhan out to Europe and North America – using…

Photo

Genomic insights into 2019-nCoV

New coronavirus: largest meta-analysis yet answers important questions

Scientists at the University of Bologna have conducted the largest analysis of coronavirus 2019-nCoV genomes sequenced so far. This analysis confirms that the virus originates in bats and shows a low…

Photo

Deadly virus

New test to identify and control Ebola variants

The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time. Whilst the risks…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG